Therapeutic potential of fractalkine: A novel approach to metastatic colon cancer

Gut

Volumn 56, Issue 3, 2007, Pages 314-316

  Brueckmann, M ^a   Borggrefe, M ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CX3C CHEMOKINE; FRACTALKINE; CHEMOKINE (C X3 C MOTIF) LIGAND 1; CHEMOKINE (C-X3-C MOTIF) LIGAND 1; MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER IMMUNIZATION; CANCER MORTALITY; CELL ADHESION; CHEMOTAXIS; COLON CANCER; CYTOTOXIC T LYMPHOCYTE; GLOMERULONEPHRITIS; HUMAN; METASTASIS; NOTE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE SUBPOPULATION; ANIMAL; COLON TUMOR; DISEASE MODEL; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY;

ANIMALS; CHEMOKINES, CX3C; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; IMMUNOTHERAPY; MEMBRANE PROTEINS; NEOPLASM METASTASIS;

EID: 34047116230     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2006.103317     Document Type: Note

References (17)

1. Mantovani A, Allavena P, Vecchi A, et al. Chemokines and chemokine receptors during activation and deactivation of monocytes and dentritic cells and in amplification of Th1 versus Th2 responses. Int J Clin Lab Res 1998;28:77-82.
2. Guo J, Chen T, Wang B, et al. Chemoattraction, adhesion and activation of natural killer cells are involved in the antitumor immune response induced by fractalkine/CXCL1. Immunol Lett 2003;89:1-7.
3. Nukiwa M, Andrani S, Zaini J, et al. Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors. Eur J Immunol 2006;36:1019-27.
4. Chen S, Bacon KB, Li L, et al. In vivo inhibition of CC and CX3C chemokine-induced leukocyte infiltration and attenuation of glomerulonephritis in Wistar-Kyoto (WKY) rats by vMIP-II. J Exp Med 1998;188:193-8.
5. Ruth JH, Volin MV, Haines GK III, et al. Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant-induced arthritis. Arthritis Rheum 2001;44:1568-81.
6. Damas JK, Boullier A, Wæhre T, et al. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy. Arterioscler Thromb Vasc Biol 2005;25:2567-72.
7. Bazan JF, Bacon KB, Hardiman G, et al. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997;385:640-4.
8. Fong AM, Robinson LA, Steeber DA, et al. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med 1998;188:1413-19.
9. Garton KJ, Gough PJ, Blobel CP, et al. Tumor necrosis factor-alpha converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem 2001;276:37993-8001.
10. Imai T, Hieshima K, Haskell C, et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997;91:521-30.
11. Yoneda O, Imai T, Goda S, et al. Fractalkine-mediated endothelial cell injury by NK cells. J Immunol 2000;164:4055-62.
12. Robinson LA, Nataraj C, Thomas DW, et al. A role for fractalkine and its receptor (CX3CR1) in cardiac allograft rejection. J Immunol 2000;165:6067-72.
13. Feng L, Chen S, Garcia GE, et al. Prevention of crescent glomerulonephritis by immunoneutralization of the fractalkine receptor CX3CR1. Kidney Int 1999;56:612-20.
14. Faussat A, Bouchet-Delbos L, Berrebi D, et al. Deregulation of the expression of the fractalkine/ fractalkine receptor complex in HIV-infected patients. Blood 2001;98:1678-86.
15. Faure S, Meyer L, Costagliola D, et al. Rapid preogression to AIDS in HIV individuals with a structural variant of the chemokine receptor CX3CR1. Science 2000;287:2274-7.
16. Ohio M, Tanaka F, Yamaguchi H, et al. The high expression of fractalkine results in a better prognosis for colorectal cancer patients. Int J Oncol 2005;26:41-7.
17. Vitale S, Cambien B, Karimdjee BF, et al. Tissue-specific differential antitumoral effect of molecular forms of fractalkine in a mouse model of metastatic colon cancer. Gut 2007;56:365-72.